X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA NOVARTIS ELDER PHARMA/
NOVARTIS
 
P/E (TTM) x -0.2 347.8 - View Chart
P/BV x 0.1 17.1 0.6% View Chart
Dividend Yield % 0.0 1.7 -  

Financials

 ELDER PHARMA   NOVARTIS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
NOVARTIS
Mar-16
ELDER PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs380982 38.7%   
Low Rs188556 33.8%   
Sales per share (Unadj.) Rs491.2252.9 194.2%  
Earnings per share (Unadj.) Rs-3.262.1 -5.1%  
Cash flow per share (Unadj.) Rs14.463.3 22.8%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs376.5363.6 103.5%  
Shares outstanding (eoy) m20.5431.96 64.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.0 19.0%   
Avg P/E ratio x-89.312.4 -721.2%  
P/CF ratio (eoy) x19.712.2 162.2%  
Price / Book Value ratio x0.82.1 35.7%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m5,83324,580 23.7%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,1791,801 121.0%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m10,0898,083 124.8%  
Other income Rs m257829 30.9%   
Total revenues Rs m10,3468,913 116.1%   
Gross profit Rs m-792234 -338.1%  
Depreciation Rs m36137 984.5%   
Interest Rs m2,7562 153,127.8%   
Profit before tax Rs m-3,6531,025 -356.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m3,7131,696 218.9%   
Tax Rs m125752 16.6%   
Profit after tax Rs m-651,986 -3.3%  
Gross profit margin %-7.82.9 -270.9%  
Effective tax rate %-3.473.4 -4.7%   
Net profit margin %-0.624.6 -2.6%  
BALANCE SHEET DATA
Current assets Rs m9,24012,678 72.9%   
Current liabilities Rs m9,9982,433 410.9%   
Net working cap to sales %-7.5126.7 -5.9%  
Current ratio x0.95.2 17.7%  
Inventory Days Days4633 141.6%  
Debtors Days Days6022 266.5%  
Net fixed assets Rs m10,12469 14,629.6%   
Share capital Rs m206160 128.7%   
"Free" reserves Rs m5,58211,460 48.7%   
Net worth Rs m7,73411,621 66.5%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88214,400 158.9%  
Interest coverage x-0.3570.5 -0.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 78.5%   
Return on assets %11.813.8 85.2%  
Return on equity %-0.817.1 -4.9%  
Return on capital %22.323.6 94.6%  
Exports to sales %3.00.7 408.0%   
Imports to sales %0.418.6 2.3%   
Exports (fob) Rs m30760 509.3%   
Imports (cif) Rs m431,503 2.9%   
Fx inflow Rs m307186 164.6%   
Fx outflow Rs m1251,821 6.9%   
Net fx Rs m181-1,635 -11.1%   
CASH FLOW
From Operations Rs m11,7542,531 464.4%  
From Investments Rs m-561-8,270 6.8%  
From Financial Activity Rs m-6,762-386 1,753.1%  
Net Cashflow Rs m4,432-6,125 -72.4%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.5 2.0 375.0%  
FIIs % 16.8 1.6 1,050.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 21.5 167.9%  
Shareholders   16,479 41,647 39.6%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS